Melphalan Tillomed

Melphalan, the active ingredient in Melphalan Tillomed, is an alkylating agent presented as an injection for intravenous use. It treats certain cancers such as multiple myeloma, ovarian cancer, melanoma, and breast cancer in adult patients.

GNH USA supplies Melphalan Tillomed as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Melphalan is an alkylating agent used in the treatment of several solid tumours and hematologic malignancies.

Multiple Myeloma: improves disease control and prolongs survival. Ovarian Cancer: used in combination regimens to reduce tumor burden. Melanoma: employed in advanced disease to achieve tumor regression. Breast Cancer: incorporated into chemotherapy protocols for metastatic disease.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis. - Fatigue: general tiredness. - Myelosuppression: reduced blood cell counts causing anemia, neutropenia, or thrombocytopenia.

Serious or Rare Side Effects: - Severe infection: due to profound neutropenia. - Acute leukemia: rare secondary malignancy. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

Prior to initiating therapy, several safety considerations should be addressed. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess renal function: adjust therapy if impairment is present. - Evaluate hepatic function: liver dysfunction may affect drug handling. - Avoid in patients with active infection: risk of worsening infection. - Pregnancy: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection; avoid concurrent use. - High-dose radiation therapy: increased risk of tissue damage. - Other alkylating agents: additive myelosuppression.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may increase melphalan exposure. - CYP450 inducers (e.g., phenobarbital): may reduce efficacy. - NSAIDs: may exacerbate renal toxicity.